Please assess the completion status of the following clinical trial:

Trial Title: Investigating the Inotropic Potential of Apelin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Healthy volunteers:~\>18yrs~Heart failure patients;~* New York Heart Failure class II-IV~* Ejection fractional \<35% or fractional shortening \<20% within previous 6months.~Exclusion Criteria:~All subjects,~* Females of child bearing age not on adequate contraception~* Lack of informed consent~* Age \<18yrs~* Current involvement in any other research study~* Systolic BP \>190 or \<100~* Malignant arrhythmias~* Renal or hepatic failure~* Haemodynamically significant aortic stenosis~* Severe or significant co-morbidity~* Pacemakers~Healthy volunteers~* Any regular medication~* Previous history of any cardiovascular disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Apelin infusion (Type: EXPERIMENTAL): 6 hour infusion of apelin peptide into circulation
- Placebo (Type: PLACEBO_COMPARATOR): Infusion of saline into systemic circulation

Based on this trial design, predict the completion outcome and termination type (if applicable).